It been a while since Anteris advised the market on internal NPV calculations. With the advances made since then there must be a reasonable reduction in risk metrics. It will be very interesting to hear there next valuation.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-2
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.02 |
Change
-0.930(4.66%) |
Mkt cap ! $365.8M | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.00 | $19.02 | $28.61K | 1.498K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 236 | $19.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 232 | 1 |
View Market Depth
| Last trade - 10.58am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.01 |
Change
-0.930 ( 4.85 %) |
||||
| Open | High | Low | Volume | ||
| $19.75 | $19.75 | $19.01 | 464 | ||
| Last updated 11.04am 17/06/2024 ? | |||||
| AVR (ASX) Chart |
